Key Highlights

  • Acumen Pharmaceuticals (NASDAQ:ABOS) trades at USD 0.24, up 14.09%, with 33.72 million shares changing hands (relative Volume 4.42) and a Market Value of USD 17.34 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Senti Biosciences (NASDAQ:SNTI) is quoted at USD 0.19, up 13.87%, on 896,820 shares and a market value of USD 5.86 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Context Therapeutics (NASDAQ:CNTX) is at USD 0.20, up 6.82%, with 1.29 million shares traded (relative volume 1.07) and a market value of USD 18.56 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Hain Celestial (NASDAQ:HAIN) is at USD 0.13, up 12.59%, on 2.72 million shares (relative volume 1.35) and a market value of USD 12.20 million on the penny stocks screen, as of the capture on November 4, 2026.

1. Acumen Pharmaceuticals (NASDAQ:ABOS)

Acumen Pharmaceuticals (NASDAQ:ABOS) told investors on October 30, 2026 that a Phase 2 study failed its main goal and that the company will wind down the program. ABOS appears here because the penny stocks screen picks out very cheap share prices, where modest orders can push a quote around and bid-ask gaps can be wide. Published coverage of the Quarterly Report placed cash, equivalents and marketable securities at USD 78.6 million at the end of September, with a quarterly net loss of USD 25.4 million, both reported before the trial outcome came out. Published coverage also cited a one-day drop of about 91% on October 30; this is a single source figure treated as approximate, which would make the latest gain a rebound from a very depressed level. The screen's market value of USD 17.34 million sits below the USD 78.6 million cash figure, a simple comparison across a screen figure and a reported one. At this scale a handful of trades can shift the price, spreads can be wide and quoted moves can flip, so a rise tells us nothing about what follows.

2. Senti Biosciences (NASDAQ:SNTI)

On October 15, 2026, Senti Biosciences (NASDAQ:SNTI) stockholders approved a Merger under which holders receive no cash at closing, but contingent value rights worth up to USD 60.0 million. A share price under USD 1 says nothing final about the business, though it can trigger Listing Rules such as the Nasdaq minimum bid price and make any Capital raise dilutive for SNTI holders. The rights would pay USD 10.0 million upon regulatory filing acceptance for SENTI-202, USD 20.0 million on FDA approval and USD 30.0 million if cumulative net sales top USD 200.0 million, all within seven years. Stockholders also backed a reverse split at a ratio between 1-for-20 and 1-for-50. This is a small, lightly traded stock, so a few orders can move the quote, spreads can be wide and a gain can fade.

3. Theriva Biologics (NYSEAMERICAN:TOVX)

Theriva Biologics (NYSEAMERICAN:TOVX) reported cash of USD 11.3 million at June 30, 2026, against a screen market value of USD 8.44 million. For TOVX, the market value and trading volume count for more than the share price: with a market value of only a few million USD, a few trades can set the quote. The company has begun dosing patients in the VIRAGE2 Phase 2a study of VCN-01 in metastatic pancreatic cancer, planned for six evaluable patients, with first data expected by the third quarter of 2027. It intends to discuss a Phase 2 and 3 retinoblastoma trial protocol with the FDA in the third quarter of 2026, and enrollment in a SYN-004 study is on hold until funding arrives. The main risk is that cash lasts only until the first quarter of 2027, so new financing is probable, and a small name can see its quoted moves reverse.

4. Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics (NASDAQ:CNTX) reported cash of USD 43 million at June 30, 2026, which management expects to cover operations through the fourth quarter of 2027. CNTX appears here because the penny stocks screen selects very low share prices, where a few orders can jolt a quote and spreads can be wide. Management stated that the cash funds operations through the fourth quarter of 2027. Its lead candidate, CTIM-76, earned FDA Fast Track Designation in April 2026, and a Phase 1b expansion is anticipated to begin in the first quarter of 2027. At this scale a modest number of orders can shift the price, spreads can be wide and quoted moves can reverse, so an advance tells nothing about the next step.

5. Hain Celestial (NASDAQ:HAIN)

Hain Celestial (NASDAQ:HAIN) has until March 22, 2027 to lift its shares back to USD 1.00 under a Nasdaq deadline. A sub-USD 1 price does not settle the question of the business, though it can bring listing rules into play, including the Nasdaq minimum bid price, and make new financing dilutive for HAIN holders. To come back into compliance the shares must close at or above USD 1.00 for at least ten straight Business days, and the company has said it could use a Reverse Stock Split if necessary. Published coverage of the Annual Report pointed to Debt of about USD 558 million due December 22, 2026, set against about USD 58 million of cash, along with Going Concern doubt; these figures come from a single source and are approximate. The core risk is a going concern doubt with debt coming due on December 22, 2026, plus a quote that can swing hard on small trades.

Where Things Stand

Based on the evidence reviewed, Hain Celestial (NASDAQ:HAIN) and SNTI show the most visible structural risk, given a going concern doubt and a merger that pays nothing in cash at closing. ABOS is winding down its program after a failed trial, TOVX has runway into the first quarter of 2027, and CNTX covers operations through the fourth quarter of 2027. All five are small names whose quotes can reverse. The penny stocks screen targets very low share prices. At these levels a handful of orders can move a quote, spreads can be wide, and listing rules, reverse splits and financing can outweigh operating results. A price move tells us little about the road ahead.